KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Research & Development: 2009-2024

Historic Research & Development for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $303.2 million.

  • Acadia Pharmaceuticals' Research & Development rose 31.86% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.8 million, marking a year-over-year increase of 28.05%. This contributed to the annual value of $303.2 million for FY2024, which is 13.76% down from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Research & Development is $303.2 million, which was down 13.76% from $351.6 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Research & Development ranged from a high of $361.6 million in FY2022 and a low of $239.4 million during FY2021.
  • Its 3-year average for Research & Development is $338.8 million, with a median of $351.6 million in 2023.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Research & Development dropped by 24.98% in 2021 and then soared by 51.02% in 2022.
  • Over the past 5 years, Acadia Pharmaceuticals' Research & Development (Yearly) stood at $319.1 million in 2020, then decreased by 24.98% to $239.4 million in 2021, then skyrocketed by 51.02% to $361.6 million in 2022, then fell by 2.75% to $351.6 million in 2023, then decreased by 13.76% to $303.2 million in 2024.